#### Minimization of a utility function for optimizing the URBB dosing frequency of amoxicillin administration in Universitäts-Kinderspital beider Basel neonates according to a fixed PK/PD index **SWISSPEDDOSE** Nationale Dosierungsdatenbank für Kinderarzneimittel Base de données nationale de posologie pédiatrique

### A. Fuchs<sup>1</sup>, J. Bielicki<sup>1,2</sup>, A. Atkinson<sup>1,3</sup>, J. Van Den Anker<sup>1,4</sup>, M. Pfister<sup>1</sup>

(1) Paediatric Pharmacology and Pharmacometrics, University of Basel Children's Hospital, Basel, Switzerland (2) Paediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St George's, University of London, UK (3) Department of Infectious Diseases, University Hospital Bern, Bern, Switzerland (4) Division of Clinical Pharmacology, Children's National Health System, Washington DC, USA

# **OBJECTIVE**

Optimize a priori amoxicillin dosing regimen by individualizing dosing frequency of 50 mg/kg dose in neonates according to weight cut-offs (CO) with the aim to:

## **RESULTS**

For a fixed dose of 50 mg/kg, optimum weight COs were 3 kg for 2 categories, and 1.5 kg and 3 kg for 3 categories. However, the difference in estimated dosing interval per weight subgroup was small for both 2 or 3 dosing categories (table):

Banca dati nazionale di posologia pediatrica

Swiss Database of Dosing Pediatric Medicinal Products


- achieve antibiotic exposure to concentrations above the minimum inhibitory concentration (MIC) during the entire dosing interval (100% T > MIC)
- while avoiding drug administered in excess and prolonged time below the MIC

## **METHOD**

Individual exposure was simulated from a popPK ARPEC patient's demographic model using Identification characteristics. optimal of individualized dosing strategies via minimization of a utility function. Dosing interval  $\tau$  and weight **CO** were the parameters to be **optimized**. The utility function implemented in NONMEM<sup>1</sup> allows quantification of

1. the risk associated with the deviation from the

Fixed dose 50 mg/kg			
2 dosing categories		3 dosing categories	
Weight (kg)	Dosing interval (hrs)	Weight (kg)	Dosing interval (hrs)
< 3	16.4	< 1.5	18.5
≥ 3	15.3	1.5 - 3	16.2
		≥ 3	15.8



treatment target (PK/PD index:100%T>MIC) i.e. aiming to achieve drug concentrations above the MIC for the entire dosing interval (efficacy)

 $Y_{1} = [\ln(100\% T > MIC) - \ln(\% T > MIC)_{individual}]^{2}$ 

2. to minimize the time that neonates are exposed to concentrations below the MIC (regrowth) i.e. for > 4 hours per dosing interval

 $Y_2 = [\mathbf{4} - (Time < MIC)_{individual}]^2$ 

3. to **minimize** the amount administered in excess (AIE) (adverse events)

$$AIE = \left(\frac{1}{\tau} - \frac{1}{\tau_{dose}}\right) / \frac{1}{\tau_{dose}}$$

## **τ** : estimated dosing interval

 $\tau_{dose}$  : dosing interval resulting in 100%T> MIC for each individual

This suggests that amoxicillin exposure might be optimal without neonatal dosing categories based on weight cut-offs when using 50 mg/kg as a fixed dose.

Driven by efficacy endpoints and for clinical implementation, a 12h interval appears to be the most convenient. In terms of efficacy, 50 mg/kg every 12h results in 93% of patients reaching 100%T>MIC and 1.5% being > 4h below the MIC after the first dose

# CONCLUSION

The method facilitate dose decision based on quantitative

$$Y_3 = [\mathbf{0} - (AIE)_{individual}]^2$$

## The utility function to minimize is

 $Y = Y_1 + Y_2 + Y_3 + \varepsilon$ 

Estimation of weight CO was a stepwise search in which the COs were restricted to take value multiples of 0.5 kg.

Single dose administered was fixed to 50 mg/kg, the non-species related breakpoint for amoxicillin resistance of 8 mg/L was used for the MIC<sup>2</sup>.

rational drug dosing using a combined utility function. This is particularly valuable in the dynamic neonatal population which exhibits highly correlated weight and age values. It was applied to body weight but it can be extended to other demographic factors that may be clinically relevant and facilitate implementation during routine clinical care. Limitation: the PK model used for simulations requires validation

#### References:

(1) Viberg A et al. J Clin Pharmacol. 2008 Nov;48(11):1270-81. (2) EUCAST. Clinical breakpoints. http://www.eucast.org/clinical\_breakpoints/ (2017-02-20)

ARPEC data are used under the kind permission of Prof. Herman Goossens and Ms Ann Versporten, University of Antwerp, and the ARPEC project group